SCHEMBL4772860

SCHEMBL4772860

COc1cc(-c2cc(CN3CCN(Cc4ccc(F)cc4)CC3)ccn2)cc(OC)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.49
AURKA O14965 1/20 0.48
ACHE P22303 1/20 0.48
BACE1 P56817 1/20 0.48
TGFBR1 P36897 1/20 0.48
ACVR1 Q04771 1/20 0.48
KCNH2 Q12809 1/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 1/20 0.47
HTT P42858 1/20 0.47
JAK2 O60674 3/20 0.47
JAK1 P23458 3/20 0.47
TYK2 P29597 2/20 0.47
JAK3 P52333 2/20 0.47
ABCB1 P08183 1/20 0.46
KMT2A Q03164 1/20 0.46
CDK1 P06493 1/20 0.44
CDK2 P24941 1/20 0.44
CASP3 P42574 1/20 0.44
CDK9 P50750 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4763673 0.95 DRD2 (0.48) MAPK1AURKAACHEBACE1TGFBR1
SCHEMBL4763764 0.92 TGFBR1 (0.49) TGFBR1ACVR1KDM4EALDH1A1JAK2
SCHEMBL4773743 0.91 TGFBR1 (0.53) ACHEBACE1TGFBR1ACVR1KDM4E
SCHEMBL6637120 0.90 TGFBR1 (0.52) ACHEBACE1TGFBR1ACVR1KDM4E
SCHEMBL4769199 0.90 WNK1 (0.51) ACHEBACE1TGFBR1ACVR1KDM4E
SCHEMBL4763699 0.90 TGFBR1 (0.51) TGFBR1ACVR1KDM4EALDH1A1JAK2
SCHEMBL4764246 0.88 BACE1 (0.51) MAPK1ACHEBACE1TGFBR1ACVR1
SCHEMBL4763891 0.88 KDM4E (0.53) TGFBR1ACVR1KDM4EALDH1A1JAK2
SCHEMBL4764307 0.87 HSP90AA1 (0.57) TGFBR1ACVR1KDM4EALDH1A1JAK2
SCHEMBL4768772 0.86 TGFBR1 (0.48) ACHEBACE1TGFBR1ACVR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1400513-B1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND KOWA CO (JP) 2008-01-09 EP disclosed
EP-1400513-A1 UNSYMMETRICAL CYCLIC DIAMINE COMPOUND Kowa Co., Ltd. (JP) 2004-03-24 EP disclosed
US-6552188-B2 Inhibit cell adhesion and cell infiltration; useful treating asthma, allergies, rheumatic diseases, arteriosclerosis, and inflammation; 2-(3,4,5-trimethoxyphenyl),4-((4-substituted piperazin-1-yl)methyl)pyridine compounds KOWA CO., LTD. (JP) 2003-04-22 US disclosed
US-20030022887-A1 Unsymmetrical cyclic diamine compound KOWA CO., LTD. (JP) 2003-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030022887-A1 Unsymmetrical cyclic diamine compound H1-0, DDAH1, AOC1 MAPK1 441/4885AURKA 3077/4885ACHE 3597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.